{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:54:56Z","timestamp":1789628096267,"version":"build-2803163510"},"reference-count":42,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Background:\u00a0Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma.\nObjective:\u00a0This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomide, radiation therapy, and surgical strategies.\nMethods:\u00a0The researchers conducted a systematic literature review for each research question on scientific databases and surveyed a panel of experts for each therapeutic procedure\u2019s specific drivers that contributed to its total cost.\nResults:\u00a0The average cost of the first year of treatment was \u20ac2,558.91 and \u20ac3,287.40 for subjects with microprolactinoma and macroprolactinoma, respectively. Follow-up costs from the second to the fifth year after initial treatment were \u20ac798.13 and \u20ac1,084.59 per year in both groups. Cabergoline had an adequate cost-utility profile, with an incremental cost-effectiveness ratio (ICER) of \u20ac3,201.15 compared to bromocriptine, based on a willingness-to-pay of \u20ac40,000 per quality-adjusted life year (QALY) in the reference economy. Endoscopic surgery was more cost-effective than cabergoline, with an ICER of \u20ac44,846.64. Considering a willingness-to-pay of \u20ac40,000\/QALY, the baseline findings show cabergoline to have high cost utility and endoscopic surgery just a tad above\u00a0that.\nConclusions:\u00a0Due to the favorable cost-utility profile and safety of surgical treatment, pituitary surgery should be considered more frequently as the initial therapeutic approach. This management choice could lead to better outcomes and an appropriate allocation of healthcare resources.<\/jats:p>","DOI":"10.33393\/grhta.2024.2601","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T07:53:10Z","timestamp":1704786790000},"page":"1-16","source":"Crossref","is-referenced-by-count":4,"title":["A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas"],"prefix":"10.33393","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1098-2648","authenticated-orcid":false,"given":"Michele","family":"Basile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-7495","authenticated-orcid":false,"given":"Ilaria","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1417-287X","authenticated-orcid":false,"given":"Roberto","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-5589","authenticated-orcid":false,"given":"Renato","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Persichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Samperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-0978","authenticated-orcid":false,"given":"Alessandro","family":"Scoppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Simona","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6043-3725","authenticated-orcid":false,"given":"Ernesto De","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-7650","authenticated-orcid":false,"given":"Emanuele","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Iat\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-8828","authenticated-orcid":false,"given":"Diego","family":"Mazzatenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maurizio Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-8357","authenticated-orcid":false,"given":"Fabio","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-7939","authenticated-orcid":false,"given":"Zuzana","family":"Mitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-0415","authenticated-orcid":false,"given":"Rosella","family":"Saulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3893-8403","authenticated-orcid":false,"given":"Simona","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cappabianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Paoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8865-0723","authenticated-orcid":false,"given":"Alessandro","family":"Bozzao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-0734","authenticated-orcid":false,"given":"Francesco","family":"Doglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-6598","authenticated-orcid":false,"given":"Francesco","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gerardo","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Laureti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1616-9105","authenticated-orcid":false,"given":"Stefano","family":"Lello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-263X","authenticated-orcid":false,"given":"Pietro","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-1603","authenticated-orcid":false,"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-3183","authenticated-orcid":false,"given":"Chiara","family":"Ruini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Settanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Silvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-8010","authenticated-orcid":false,"given":"Franco","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Papini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Americo","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"10945","doi-asserted-by":"crossref","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290 PMID:31326373","DOI":"10.1016\/j.beem.2019.101290"},{"key":"10946","doi-asserted-by":"crossref","unstructured":"Vroonen L, Daly AF, Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 2019;109(1):20-27. https:\/\/doi.org\/10.1159\/000497746 PMID:30731464","DOI":"10.1159\/000497746"},{"key":"10947","doi-asserted-by":"crossref","unstructured":"Olarescu NC, Perez-Rivas LG, Gatto F, et al; EYRC (ENEA Young Researcher Committee). Aggressive and Malignant Prolactinomas. Neuroendocrinology. 2019;109(1):57-69. https:\/\/doi.org\/10.1159\/000497205 PMID:30677777","DOI":"10.1159\/000497205"},{"key":"10948","doi-asserted-by":"crossref","unstructured":"de Laat JM, Dekkers OM, Pieterman CR, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the Dutch MEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100(9):3288-3296. https:\/\/doi.org\/10.1210\/JC.2015-2015 PMID:26126205","DOI":"10.1210\/JC.2015-2015"},{"key":"10949","doi-asserted-by":"crossref","unstructured":"Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373-E383. https:\/\/doi.org\/10.1210\/jc.2009-2556 PMID:20685857","DOI":"10.1210\/jc.2009-2556"},{"key":"10950","doi-asserted-by":"crossref","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Leese GP. Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect. 2017;6(8):580-588. https:\/\/doi.org\/10.1530\/EC-17-0171 PMID:28954743","DOI":"10.1530\/EC-17-0171"},{"key":"10951","unstructured":"Iannone P, Coclite D, Fauci AJ, Graziano G, Napoletano AM. [Italian guidelines in accordance with the new National Guidelines System: critical issues and perspectives]. Recenti Prog Med. 2017;108(9):360-362. https:\/\/doi.org\/10.1701\/2745.27986 PMID:28901343"},{"key":"10952","unstructured":"Morgano GP, Parmelli E, Amato L, et al. [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. Recenti Prog Med. 2018;109(5):272-293. https:\/\/doi.org\/10.1701\/2902.29246 PMID:29771250"},{"key":"10953","doi-asserted-by":"crossref","unstructured":"Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. https:\/\/doi.org\/10.1210\/jc.2010-1692 PMID:21296991","DOI":"10.1210\/jc.2010-1692"},{"key":"10954","unstructured":"Sistema Nazionale Linee Guida dell\u2019Istituto Superiore di Sanit\u00e0. Terapia dei prolattinomi. 2022. https:\/\/www.iss.it\/documents\/20126\/8403889\/LG188-AME_Terapia-prolattinomi.pdf\/307919a6-d35b-b5b7-ec4c-8afc4a5eb093?t=1678805522649 (Accessed April 2023)"},{"key":"10955","doi-asserted-by":"crossref","unstructured":"Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522. https:\/\/doi.org\/10.1210\/jcem.84.7.5810 PMID:10404830","DOI":"10.1210\/jcem.84.7.5810"},{"key":"10956","doi-asserted-by":"crossref","unstructured":"Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85(6):2247-2252. https:\/\/doi.org\/10.1210\/jcem.85.6.6657 PMID:10852458","DOI":"10.1210\/jc.85.6.2247"},{"key":"10957","doi-asserted-by":"crossref","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265-273. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02562.x PMID:16886971","DOI":"10.1111\/j.1365-2265.2006.02562.x"},{"key":"10958","doi-asserted-by":"crossref","unstructured":"Cozzi R, Ambrosio MR, Attanasio R, et al. Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol. 2022;186(3):1-P33. https:\/\/doi.org\/10.1530\/EJE-21-0977 PMID:35000899","DOI":"10.1530\/EJE-21-0977"},{"key":"10959","doi-asserted-by":"crossref","unstructured":"Molitch ME. Dopamine resistance of prolactinomas. Pituitary. 2003;6(1):19-27. https:\/\/doi.org\/10.1023\/A:1026225625897 PMID:14674720","DOI":"10.1023\/A:1026225625897"},{"key":"10960","doi-asserted-by":"crossref","unstructured":"Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019;109(1):42-50. https:\/\/doi.org\/10.1159\/000495775 PMID:30481756","DOI":"10.1159\/000495775"},{"key":"10961","doi-asserted-by":"crossref","unstructured":"Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349(21):2023-2033. https:\/\/doi.org\/10.1056\/NEJMoa022657 PMID:14627787","DOI":"10.1056\/NEJMoa022657"},{"key":"10962","doi-asserted-by":"crossref","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(3):e32-e41. https:\/\/doi.org\/10.1210\/clinem\/dgz144 PMID:31665485","DOI":"10.1210\/clinem\/dgz144"},{"key":"10963","doi-asserted-by":"crossref","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N. Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol. 2016;175(3):R89-R96. https:\/\/doi.org\/10.1530\/EJE-16-0087 PMID:27207245","DOI":"10.1530\/EJE-16-0087"},{"key":"10964","doi-asserted-by":"crossref","unstructured":"Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012;15(1):71-83. https:\/\/doi.org\/10.1007\/s11102-011-0347-7 PMID:21918830","DOI":"10.1007\/s11102-011-0347-7"},{"key":"10965","doi-asserted-by":"crossref","unstructured":"Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012;166(5):779-786. https:\/\/doi.org\/10.1530\/EJE-11-1000 PMID:22301915","DOI":"10.1530\/EJE-11-1000"},{"key":"10966","doi-asserted-by":"crossref","unstructured":"Sheplan Olsen LJ, Robles Irizarry L, Chao ST, et al. Radiotherapy for prolactin-secreting pituitary tumors. Pituitary. 2012;15(2):135-145. https:\/\/doi.org\/10.1007\/s11102-011-0348-6 PMID:21948464","DOI":"10.1007\/s11102-011-0348-6"},{"key":"10967","doi-asserted-by":"crossref","unstructured":"Hung YC, Lee CC, Yang HC, et al. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study. J Neurosurg. 2019;133(3):1-10. https:\/\/doi.org\/10.3171\/2019.4.JNS183443 PMID:31374549","DOI":"10.3171\/2020.12.JNS183443a"},{"key":"10968","doi-asserted-by":"crossref","unstructured":"Trouillas J, Delgrange E, Wierinckx A, et al. Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours. Neuroendocrinology. 2019;109(1):70-76. https:\/\/doi.org\/10.1159\/000499382 PMID:30943495","DOI":"10.1159\/000499382"},{"key":"10969","doi-asserted-by":"crossref","unstructured":"McCormack A, Dekkers OM, Petersenn S, et al; ESE Survey Collaborators. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265-276. https:\/\/doi.org\/10.1530\/EJE-17-0933 PMID:29330228","DOI":"10.1530\/EJE-17-0933"},{"key":"10970","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press; 2015:253-255."},{"key":"10971","doi-asserted-by":"crossref","unstructured":"Perazzo H, Jorge MJ, Silva JC, et al. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil. BMC Gastroenterol. 2017;17(1):119. https:\/\/doi.org\/10.1186\/s12876-017-0676-8 PMID:29169329","DOI":"10.1186\/s12876-017-0676-8"},{"key":"10972","doi-asserted-by":"crossref","unstructured":"Edwards RT, C\u00e9illeachair A, Bywater T, Hughes DA, Hutchings J. Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis. BMJ. 2007;334(7595):682. https:\/\/doi.org\/10.1136\/bmj.39126.699421.55 PMID:17350965","DOI":"10.1136\/bmj.39126.699421.55"},{"key":"10973","doi-asserted-by":"crossref","unstructured":"Griffith GL, Edwards RT, Gray J, et al. Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer. Br J Cancer. 2004;90(10):1912-1919. https:\/\/doi.org\/10.1038\/sj.bjc.6601794 PMID:15138471","DOI":"10.1038\/sj.bjc.6601794"},{"key":"10974","unstructured":"Kinsella S. Ten lessons for micro-costing in health economics. Department of Economics, Kemmy Business School, University of Limerick; 2008."},{"key":"10975","unstructured":"Morris S, Devlin N, Parkin D, Spencer A. Economic analysis in healthcare. John Wiley & Sons; 2012."},{"key":"10976","doi-asserted-by":"crossref","unstructured":"Fattore G. Proposta di Linee Guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEcon Ital Res Artic. 2009;11(2):83-93. https:\/\/doi.org\/10.1007\/BF03320660","DOI":"10.1007\/BF03320660"},{"key":"10977","unstructured":"Ministero della Salute M. Tariffario delle Prestazioni Specialistiche Ambulatoriali. http:\/\/www.salute.gov.it\/portale\/temi\/p2_6.jsp?id=1767&area=programmazioneSanitariaLea&menu=lea. Accessed July 2023."},{"key":"10978","unstructured":"Agenzia per la Rappresentanza Negoziale delle Pubbliche Amministrazioni (ARAN). https:\/\/www.aranagenzia.it\/statistiche-e-pubblicazioni\/dati-statistici.html. Accessed July 2023."},{"key":"10979","unstructured":"Agenzia Italiana del Farmaco (AIFA). Lista di Trasparenza AIFA, Farmaci di Fascia H. https:\/\/www.aifa.gov.it\/liste-farmaci-a-h. Accessed July 2023."},{"key":"10980","unstructured":"Agenzia Italiana del Farmaco (AIFA). Lista di Trasparenza AIFA, Farmaci di Fascia A. https:\/\/www.aifa.gov.it\/liste-farmaci-a-h. Accessed July 2023."},{"key":"10981","doi-asserted-by":"crossref","unstructured":"Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK. Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg. 2016;87:65-76. https:\/\/doi.org\/10.1016\/j.wneu.2015.10.090 PMID:26548828","DOI":"10.1016\/j.wneu.2015.10.090"},{"key":"10982","doi-asserted-by":"crossref","unstructured":"Russo P, Zanuzzi M, Carletto A, Sammarco A, Romano F, Manca A. Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service. PharmacoEconomics. 2023;41(1):107-117. https:\/\/doi.org\/10.1007\/s40273-022-01215-w PMID:36434415","DOI":"10.1007\/s40273-022-01215-w"},{"key":"10983","unstructured":"Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in healthcare. Vol 3. Oxford: OUP; 2010."},{"key":"10984","doi-asserted-by":"crossref","unstructured":"Baussart B, Villa C, Jouinot A, et al. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur J Endocrinol. 2021;185(6):783-791. https:\/\/doi.org\/10.1530\/EJE-21-0293 PMID:34605772","DOI":"10.1530\/EJE-21-0293"},{"key":"10985","doi-asserted-by":"crossref","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, et al; Pituitary Society, Expert Group on Pituitary Tumors. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary. 2017;20(5):489-498. https:\/\/doi.org\/10.1007\/s11102-017-0838-2 PMID:28884415","DOI":"10.1007\/s11102-017-0838-2"},{"key":"10986","doi-asserted-by":"crossref","unstructured":"Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180-3186. https:\/\/doi.org\/10.1210\/jcem.87.7.8645 PMID:12107221","DOI":"10.1210\/jcem.87.7.8645"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/2601\/3420","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/2601\/3421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/2601\/3422","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/2601\/3421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T07:53:25Z","timestamp":1704786805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/2601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2024.2601","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,9]]}}}